nefextinib

Nefextinib (MAX‑40279) is an orally bioavailable small molecule multi-target tyrosine kinase inhibitor developed by Maxinovel Pharmaceuticals. It acts as a dual inhibitor of fibroblast growth factor receptor (FGFR) and FMS-like tyrosine kinase 3 (FLT3), including mutant forms of FLT3. Nefextinib also inhibits other kinases such as hematopoietic progenitor kinase 1 (HPK1), Janus kinases (JAKs), platelet-derived growth factor receptors (PDGFRs), and vascular endothelial growth factor A receptor (VEGF-A). By inhibiting these targets, nefextinib blocks signal transduction pathways involved in tumor cell proliferation and survival. The drug is being investigated primarily for the treatment of acute myeloid leukemia (AML), where FLT3 mutations are common and associated with poor prognosis. It is also under clinical investigation for advanced solid tumors, gastric cancer, esophageal cancer, myelodysplastic syndromes (MDS), and idiopathic pulmonary fibrosis[1][2][6][7].

Brand names

nefextinib

Other names

7-(4-Fluoro-2-methoxyphenyl)-6-methyl-N-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)thieno(3,2-d)pyrimidin-2-amineUNII-DL772G3NN7UNII-DL-772G3NN7UNII-DL 772G3NN72070931-57-4